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ABSTRACT

Cardiovascular disease is the leading cause of death worldwide.
Coronary Artery Disease (CAD) accounts for the majority of those
deaths.

Observational studies have identified risk factors that

have been helpful in lowering the death rate, including
hypertension, high cholesterol, diabetes, smoking, physical
inactivity and poor diet. The effects of these risk factors on
CAD remain unclear.

To clarify the effect of three amino acids,

alanine, glutamine, and glycine on CAD I applied a two sample
Mendelian randomization analysis to extensively genotyped
observational data.

In a sample with up to 184,000 individuals

and approximately 60,000 controls, SNPs that reached genome wide
significance with each amino acid were identified.
equilibrium was assessed for each SNP.

Linkage

Known pleiotropy was

assessed using the phenoscanner database.

Unknown pleiotropy

was assessed using MR-Egger. Using the IVW approach, the odds of
CAD was 0.89 lower per one standard deviation of genetically
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determined higher level of alanine and was statistically
significant (95% confidence interval (CI) (0.80-0.99). The odds
of CAD was 1.09 higher per one standard deviation of genetically
determined higher level of glutamine and was not statistically
significant (95% confidence interval (CI) (0.99-1.19).

The odds

of CAD was 0.94 lower per one standard deviation of genetically
determined higher level of glycine and was statistically
significant (95% confidence interval (CI) (0.91-0.98). After
sensitivity analyses suggested pleiotropic effects, the analysis
was repeated, removing SNPs with known pleiotropy.
remained the same for all three amino acids.

Results

MI was not

statistically significantly associated with any of the amino
acids.

This study provides genetic validation that alanine

could be a new target of intervention to prevent the leading
cause of global morbidity and mortality. Glutamine should be
investigated further to determine its status as a risk factor
for CAD.

Glycine may decrease the risk of coronary artery

disease however additional research is needed.
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Introduction(overall)
Specific Aims
Aim 1: (Alanine)
To estimate the causal effect of alanine on coronary artery
disease (CAD) and myocardial infarction (MI)using instrumental
variable analysis with a genetic instrument, i.e., Mendelian
randomization.
Hypothesis 1:

A genetically higher level of alanine is causally

associated with a lower risk of CAD.
Aim 2: (Glutamine)
To estimate the causal effect of glutamine on CAD/MI using
instrumental variable analysis with genetic instruments, i.e.,
Mendelian randomization.
Hypothesis 2: A genetically higher level of glutamine is
causally associated with a lower risk of CAD and MI.
Aim 3: (Glycine)
To estimate the causal effect of glycine on CAD/MI using
instrumental variable analysis with genetic instruments, i.e.,
Mendelian randomization.
Hypothesis 3: A genetically higher level of glycine is causally
associated with a lower risk of CAD.
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Background
Cardiovascular Disease
Cardiovascular disease (CVD) is the leading cause of death
worldwide.[1, 2] The World Health Organization (WHO) estimates
that in 2016, 17,900,00 deaths, or 31% of all deaths, were from
CVD.[2] In the United States in 2015, about one in four deaths,
or approximately 610,000 deaths, were due to CVD.[3-5] Coronary
artery disease (CAD) accounted for 42% of all CVD deaths
worldwide in 2015, or approximately 7.4 million deaths, while
CAD accounted for about 60% of all CVD deaths in the United
States, or approximately 375,000 deaths.[3, 4, 6-11]

Observational epidemiological studies have identified numerous
risk factors for CAD, including hypertension, hyperlipidemia,
smoking, obesity, diabetes, unhealthy diet, and physical
inactivity.[6, 12-21] However, a large proportion of CVD events
occur in individuals with low predicted-risk based on
established risk factors.[22] Furthermore, risk stratification
models predict higher CAD for men than women at the same levels
of known risk factors.[16-21, 23] Randomized controlled trials
(RCTs)[24] have identified that pharmacotherapies capable of
mitigating CAD risk factors and CAD have had inconsistent
results.[15] How known risk factors and other factors combine to
cause CAD remains poorly understood,[6, 25-27] and the elements
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of a healthy diet, including fat, protein, carbohydrates,
vitamins and minerals have proved difficult to establish,
begging the question “does diet matter?”[28]

Meta-analyses of

observational studies do not always draw the same conclusion
about the relationship between protein consumption and
CAD/myocardial infarction (MI).[29-32] The building blocks of
proteins are amino acids, and their relationship with CAD/MI is
not clearly documented in the literature. The mixed results of
observational studies provide a justification for exploring the
relationship of amino acids, such as alanine, glutamine, and
glycine with CAD/MI.
Considerable opportunity to identify new casual factors and
treatments for CAD/MI remain. This study will use Mendelian
randomization (MR) to estimate the effects of key amino acids on
CAD/MI. MR has several advantages when compared to conventional
observational studies and is being increasingly used because it
overcomes some major limitations of observational study designs,
including unmeasured confounding. This MR study will lead to a
better understanding of the causes of CAD/MI.

Observational studies have begun investigating

the relationship

of amino acids to health and in particular, CAD.[33]

Some of

these studies have identified amino acids that seem to be
protective against metabolic diseases such as diabetes or CAD,
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and others have identified amino acids that are likely risk
factors for metabolic diseases or CAD. In many cases, it remains
unclear if biomarkers such as amino acids are merely correlated
with CAD/MI, or causally related.[28, 34-44]

Moreover, if they

are causal, the underlying mechanism that leads to CAD is
unclear.

Amino Acids
Glutamine, glycine, and alanine have been established in animal
studies to be linked with heart function and heart disease.[3436, 40-42, 45-48]

Glutamine is commonly found in nuts, which

observational studies and RCTs have found to be cardioprotective.[44, 49-51] Animal model and small RCT studies have
found that glutamine improves postoperative outcomes and
restores the heart to normal function more quickly than without
glutamine supplements.[38, 47, 48]

Similarly, glycine studies

have shown an inverse relationship with CAD and CAD risk factors
such as hypertension. Alanine studies have shown a paradoxical
relationship with diabetes, a risk factor for CAD, in light of
the beneficial role that alanine plays in glucose homeostasis
and the increased alanine observed during cardiac events.[52-54]

Glutamine and glycine are conditionally-essential amino
acids.[39, 40]

This means under normal circumstances the body
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produces the necessary amount of these amino acids for the
biosynthesis of proteins.

However, in conditions such as

injury and stress, the body may supplement these amino acids
through dietary intake.[37] Glutamine is found in a variety of
foods, including nuts.[49-51] The most relevant glutamine
producing human tissue is muscle, accounting for the majority of
the glutamine produced by the body.[39] Glycine is most notably
found in gelatin and is a major component of collagen, which is
abundant in blood vessels and the gut, among other fibrous
tissues.[36, 40, 42, 55, 56]
Glutamine is found in many supplements used by athletes
because it helps signal cell growth and increases water
retention in muscle cells.[34] It is commonly found in walnuts
and other nuts.[51]

An RCT in 2011 assessed the cardio-

protective effects of glutamine on patients with CAD following
open heart surgery.[38] Clinical tests after surgery found that
glutamine improved heart functioning in the experimental
arm.[39] In an animal experiment, researchers reported that
post-ischemic reperfusion of a rat heart with glutamine restored
normal cardiac output.[41] A meta-analysis of 53 RCT studies
found moderate to weak evidence that glutamine supplementation
would influence outcomes such as infection and recovery from
surgery and other critical illness.
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However, they found no

effect on the risk of mortality or length of intensive care unit
(ICU) stay.[39]

Glycine is an amino acid involved in anti-oxidative reactions
and collagen formation.[56]

Many observational studies have

shown an inverse association of glycine with hypertension and
type two diabetes.[42]

A 2016 RCT assessed the relationship of

plasma glycine and acute myocardial infarction in patients with
stable angina. They reported that glycine was inversely
associated with the risk of MI.[56] They found a stronger
association in patients with apolipoprotein B, low density
lipoprotein cholesterol, or apolipoprotein A-1 above the
median.[56]

Other studies have reported the positive effects

of glycine on vascular health.[42]

Glycine has been reported to

stabilize platelets, reduce the size of the ischemia injury upon
reperfusion, correct elevated blood pressure and normalize serum
triglycerides.[55, 56] While these studies in rats and humans
have reported an inverse relationship with glycine and CAD or
CAD related risk factors, they have not compared glycine levels
in those with to those without cardiovascular disease.

Alanine is a non-essential amino acid, meaning that the human
body can produce the amount required and no diet source is
needed to supplement endogenously produced alanine.
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Alanine is

found in red meat.

There have been some studies that reported

an association between the levels of alanine in the urine and
hypertension, diet, cholesterol, and body mass index (BMI),
however, these studies have not measured dietary alanine or
plasma alanine levels.

Another study found that higher serum

levels of alanine were associated with the development of type 2
diabetes.[57]

Alanine and glutamine are considered the most important amino
acids in the blood and are the only amino acids that are taken
up or released by human skeletal muscle.[36] Once alanine is
synthesized, it is converted to pyruvate and is critical in
blood sugar management.[36]

Animal studies have reported that

heart tissue releases alanine only after a CAD event, otherwise
the heart only releases alanine under stress.[48, 58] In another
study, researchers used the Hoorn cohort study data to assess
the relationship between elevated alanine serum levels and
actual CAD events at 10-year follow up.[59]

The study found an

age- and sex-adjusted two-fold increased hazard of experiencing
a CAD event at the 10-year follow up point. Furthermore, when
adjusted for the most well-known CAD risk factors, the hazard
ratio for those with elevated alanine was 1.88, suggesting an
independent pathway of alanine from the known risk factors. The
effect of amino acids, such as alanine, on glucose metabolism
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are well established, however, the net impact on glucose
homeostasis remains unclear.[54]

The literature contains

reports of both positive and negative impacts of amino acids on
glycemic regulation and metabolic syndrome.[54]

Alanine may be

a marker of an underlying etiology relating to the paradoxical
association of diabetes with CAD at the population level.
However, the discrepancy reported in these studies generates
more questions than answers about the relationship of alanine to
CAD and in each case, these studies establish an association but
do not establish a causal relationship.[54]
The existing literature suggests inconsistent effects of
alanine, glycine, and glutamine on CVD and CVD related risk
factors.

A large RCT with CAD events as the primary outcome

would be definitive, but costly. Additionally, randomly
assigning research participants to alter amino acid consumption
to determine the effect on CAD would be impractical and
difficult to implement, as modifying diet on a long-term basis
presents a compliance challenge and the outcome of interest
takes decades to develop. It would also take several years and
be difficult to justify with such little evidence of the
benefits of glutamine and glycine.
This difficulty justifies a novel methodological approach
that assesses the effects of risk factors according to
genetically determined serum levels of glycine, glutamine, and
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alanine.

Mendelian randomization (MR) has emerged as a popular

epidemiological method to obtain unconfounded causal
estimates.[60-62]
Methods/Mendelian Randomization
Epidemiological studies fall into two general categories:
experimental and observational studies. Experimental studies are
characterized by the random assignment of the exposure.
Observational studies can be designed in a variety of ways;
however, none lend themselves to estimating causal relationships
unequivocally, because of the risk of selection bias and
confounding.

In health-related research, the randomized control trial (RCT)
is the defining experimental study design. In the RCT, study
participants are randomly assigned to a study arm, receiving one
of several interventions or no intervention entirely by chance.
This approach ensures that any measured, and, more importantly,
unmeasured confounding is equally distributed across the study
arms, minimizing the risk of spurious or erroneous findings.
Blinding of all those involved with an RCT further strengthens
the findings. However, RCTs are time-consuming and expensive.
Moreover, not all exposures can feasibly be randomized.
Observational studies may complement some of the limitations of
RCTs but are not without limitations of their own.
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Determining

a causal relationship between a risk factor and health outcome
in observational studies often relies on making some untestable
and unlikely assumptions, such as no unmeasured confounding and
no selection bias.

Mendelian randomization (MR) uses genetic variants as
instrumental variables for modifiable risk factors that affect
population health.[63] MR utilizes the econometrics method of
instrumental variable (IV) analysis with genetic variants as the
IV and offers a novel approach to estimating causal effects from
observational studies. The principle underlying MR originates
from the “The Law of Independent Assortment,” also known as
Mendel’s second law, which states that inheritance of one trait
is independent of other traits, thus allowing for the use of
observational data with genetic variants as a natural
experiment.[63, 64] MR is the use of data from nonexperimental
studies to determine the causal effect of a phenotype on a
disease outcome by leveraging the random assignment of genetic
material at birth. Genetic variants, being fixed at conception,
support causal inference by minimizing confounding.[63] As the
knowledge of the human genome has grown, and access to genetic
data increased, researchers have identified an increasing number
of genetic determinants of common exposures.
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As of 2015, genome-wide association studies had identified 46
loci directly linked to CAD, yet a majority of these loci have
no apparent relation to cholesterol or other classical risk
factors.[65] Evans and Smith (2015), note that since the formal
presentation of the MR approach, an increasing number of
mentions appear in reviews of scientific abstracts of peerreviewed publications, with a steeply increasing trajectory.[66]

The first use of the term Mendelian randomization was in 1991 to
describe a means of obtaining unbiased causal estimates when
comparing bone marrow transplant with chemotherapy outcomes in
the treatment of leukemia.[62] The first generation of genomewide association Studies (GWAS) were used to show that several
genetic variants were significantly associated with CAD in
2007.[67] The MR approach has been used to elucidate causal
relationships in several areas of observational epidemiology,
including the causal role of body mass index on blood
pressure,[68, 69] and in evidence against the causal role of Creactive protein in CAD or atherosclerosis.[33, 70-74] MR has
been used extensively in CAD research, for example, to
demonstrate that C-reactive protein levels are not causally
associated with CAD, whereas lipoprotein(a) (Lp[a]) levels are
causally associated with CAD, and to further our understanding
of cardiovascular therapies, such as statins.[75, 76]
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With the increased availability of molecular profiling
techniques, particular interest has been shown in identifying
novel biomarkers for cardiovascular or metabolic risk.[33] These
methods have increased the availability of observational data
sources that include genetic information to examine different
exposures using MR to assess causal effects.[26, 62, 66, 76-80]
This dissertation project will apply MR to publicly available
data to evaluate the causal effect of three amino acids,
specifically alanine, glutamine, and glycine, on the risk of CAD
in adults.[26, 79, 80]

MR is a very powerful technique, but it does have strong
assumptions that must be met to obtain a valid estimate. The
assumptions of MR can be most clearly conveyed using a directed
acyclic graph (DAG). The DAG for MR shows the causal
relationships between the genetic instrument (Z), the modifiable
risk factor (X), the outcome (Y) and the (known or unknown,
measurable or non-measurable) confounders (U), as shown in
Figure 1.[60-62, 66, 77, 78]
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Figure 1. Directed Acyclic Graph for Mendelian Randomization[33,
78]
modifiable risk factor
Z

X

Y

outcome

Instrument
(genetic
variant)
U
confounders

In an RCT, generally a treatment or other preventive measure is
randomly assigned and so is not confounded. MR is instrumental
variable analysis with genetic instruments.[60-62, 66, 77, 78]
MR is based on the premise of random allocation of alleles at
time of gamete formation, and hence is thought to be independent
of confounding factors[60-62, 66, 77, 78, 81-84]. MR
approximates RCT study design in this respect. However, it is
important to note that the DAG shown in Figure 1 requires three
key assumptions to be valid. These assumptions are implicit in
the DAG, and normally expressed as
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1) Relevance: The instrumental variables strongly predict the
exposure
2) Independence: The instrumental variable is not confounded
by the confounders of the exposure outcome relation
3) Exclusion-restriction: The instrumental variable only
affects the outcome through the exposure, i.e., no
pleiotropy

The purpose of this study is to better understand the causal
relationship of three amino acids: glycine, glutamine and
alanine with CAD. However, the casual mechanism of the RCT may
more closely resemble the real-world relationship of the
exposure with disease than the mechanism evaluated in an MR.
First, the exposure that is assessed in the MR is a lifelong
difference between genetic groups, while most RCTs and
observational studies of CAD/MI are conducted in mature
individuals.

In this case, canalization, or an individual

developing a compensatory mechanism in response to prolonged
higher or lower levels of the exposure, is a possibility.

Also,

the prolonged exposure time assessed in the MR analysis could
represent a cumulative effect of the exposure over time, rather
than the acute response to a larger dose in a shorter period of
time.

24

Second, some diseases are irreversible at a certain point of
progression.

No RCT or observational study could be designed

that would be able to replicate the protective effects of
reducing a harmful exposure that would be a result of genetic
effects.

The efficacy of acute responses to sudden large increases in a
harmful exposure cannot be assessed by a MR analysis.

However,

interest is usually in the lifelong effects of usual levels of
exposure on disease.

MR is an advantageous approach in this

regard, as it is not possible to design an RCT that would assess
lifelong average usual levels of exposure.

Alanine, glutamine and glycine and their relationship to CAD
have yet to be evaluated using MR, instrumental variable
analysis with genetic instruments.

Paper 1(Alanine)
Abstract/Summary

Cardiovascular disease (CVD) is the leading cause of death
worldwide. CVD is poorly understood.
25

Little attention has been

given to the potential cardioprotective effects of alanine in
humans.

The relationship has primarily been explored in vitro

and in animal models.

Few observational studies have explored

the effect of alanine on heart disease.

To clarify we assessed

whether people with genetically higher levels of alanine had
lower coronary artery disease (CAD) and myocardial infarction
(MI) risk. We used a two sample Mendelian randomization study.
Six SNPs strongly associated (genome wide significant) with
alanine were applied to large extensively genotyped CAD and MI
studies to obtain unconfounded estimates.

A one standard

deviation increased level of alanine was found to protect
against CAD (odds ratio (OR) 0.89, 95% confidence interval (CI)
0.80-0.99) but not MI (OR 0.90, 95% CI 0.80-1.02). Sensitivity
analysis supports these findings.

Our findings are consistent

with the limited observational evidence, in vitro and animal
studies.

These findings genetically validate alanine as a

potential target of intervention in CAD.

Future clinical

research is needed to better understand the mechanism through
which alanine influences CAD and to develop effective treatment
interventions that include alanine.
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Introduction
Cardiovascular disease (CVD) is the leading cause of death
worldwide.[1, 2] The World Health Organization (WHO) estimates
that in 2016, 17,900,00 deaths, or 31% of all deaths, were from
CVD.[2] In the United States in 2015, about one in four deaths,
or approximately 610,000 deaths, were due to CVD.[3-5] Coronary
artery disease (CAD) accounted for 42% of all CVD deaths
worldwide in 2015, or approximately 7.4 million deaths, while
CAD accounted for about 60% of all CVD deaths in the United
States, or approximately 375,000 deaths.[3, 4, 6-11]

Observational epidemiological studies have identified numerous
risk factors for CAD, including hypertension, hyperlipidemia,
smoking, obesity, diabetes, unhealthy diet, and physical
inactivity.[12-14] Yet, how diet, including protein, causes CAD
remains poorly understood.[6, 25-27] Meta-analyses of
observational studies do not always draw the same conclusion
about the relationship between protein consumption and
CAD/myocardial infarction (MI).[29-32]

Alanine is a non-essential amino acid, meaning that the human
body can produce the amount required and that no diet source is
needed to supplement endogenously produced alanine.[36] Alanine
can also be obtained from diet, and is found in red meat[85].
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Alanine levels have been shown to deviate from normal in
response to cardiac insult, but studies of alanine and CAD have
not established a clear association.[86] There have been some
studies that reported associations between levels of alanine in
the urine and hypertension, diet, cholesterol and body mass
index (BMI); however, these studies did not measure dietary
alanine or plasma alanine levels.[45, 87] Some studies have
found that higher serum levels of alanine may protect against
CAD.[52-54] Other studies have shown that increased levels of
alanine are associated with CAD and other CVD.[88-91] However
higher levels of alanine appear to mitigate some type 2 diabetes
symptoms, in particular by activating an adenosine monophosphate
(AMP)-activated protein kinase nutrient sensor.[88] Alanine may
be a marker of an underlying etiology explaining the paradoxical
association of diabetes with CAD at the population level.[54]
However, the inconsistencies reported in these studies have
generated more questions than answers about the relationship of
alanine to CAD, and in each case, these studies established an
association but did not establish a causal relationship.[54]

There remains a considerable opportunity to identify new casual
factors and treatments for CAD/MI. This study will use Mendelian
randomization (MR) to estimate the effects of alanine on CAD/MI.
MR has several advantages when compared to conventional
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observational studies and is being increasingly used because it
overcomes some major limitations of observational study designs,
including unmeasured confounding. MR uses genetic variants as
instrumental variables for modifiable risk factors that affect
population health.[63] The principle underlying MR originates
from the “The Law of Independent Assortment,” also known as
Mendel’s second law, which states that inheritance of one trait
is independent of other traits, thus allowing use of
observational data with genetic variants as natural
experiments.[63, 64] Genetic variants, being fixed at
conception, support causal inference by minimizing
confounding.[63]

Methods

MR depends on three assumptions.

The relevance, independence

and exclusion restriction assumptions are key in selecting valid
instrumental variables.

The relevance assumption means that the

genetic instruments predict the exposure reliably. The relevance
assumption is assured by selecting single nucleotide
polymorphisms (SNPs) strongly associated with the exposure of
interest, ideally at genome wide significance, from genome-wide
association studies (GWAS).[63] The independence assumption
means that the genetic instruments are not associated with
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confounders of the exposure outcome relation. The independence
assumption requires that potential confounders of the exposure
outcome relation do not confound the genetic variant outcome
relation, to minimize the possibility of confounding.[63, 92]
The exclusion-restriction assumption means that the genetic
instruments are only associated with the outcome via the
exposure. The exclusion restriction assumption is assessed from
biological knowledge of the effects of the genetic instruments,
known associations of the genetic instruments with other factors
and statistical tests for pleiotropy.
Contributed data was corrected for population stratification,
which has been shown to occur even in single ethnicity
populations. Ancestry and the non-random distribution of SNPs
was corrected for using genomic control by adjusting for
principal components.

Genetic associations with alanine
Genetically determined levels of alanine were obtained from a
GWAS.[93, 94] The Computational Medicine extended GWAS combined
data from 11 genetic studies and 14 data sources for a total
sample size of 24,925 individuals of European descent (Finland,
Estonian, Netherlands and Germany).[93, 94] The mean age of the
study participants was 44.6 years. The individual study average
ages ranged from 31.2 to 61.3 years. Women were 55% of the total
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sample, and individual study samples ranged from 37% to 64%
female.[93, 94] SNPs strongly and independently associated with
alanine (p<5x10-8) were selected.[93, 94] The MR-Base “clumping”
function was used to identify correlations between the chosen
SNPs,[95] and only uncorrelated SNPs were retained (r 2<0.001).
SNP effects on CAD/MI via physiologic pathways other than
alanine (pleiotropy) were assessed from a comprehensive genotype
to phenotype cross-reference, PhenoScanner.[96, 97]

Genetic associations with CAD and MI
Data on coronary artery disease / myocardial infarction have
been contributed by the CARDIoGRAMplusC4D. Data have been
downloaded from www.CARDIOGRAMPLUSC4D.ORG. CARDIoGRAMplusC4D
1000 Genomes is a CAD and MI case (n=60,801)-control (n=123,504)
study, extensively genotyped using the 1000 Genomes catalog. The
majority (77%) of the participants were of European ancestry;
13% and 6% were of South Asian (India and Pakistan) and East
Asian (China and Korea) ancestry, respectively, with smaller
samples of Hispanic and African Americans. The mean age was
about 56.9 years, with genetic associations adjusted for study
specific covariates. Phenotyping of CAD, MI or both, were based
on medical records, clinical diagnosis, procedures that indicate
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CAD, medications or symptoms that indicate angina or from selfreported CAD.

Statistical analysis
Associations of alanine with CAD/MI were obtained from separate
sample instrumental variable analysis with genetic instruments.
SNP-specific Wald estimates (ratio of SNP on CAD/MI to SNP on
alanine) of the effect of alanine on CAD/MI were obtained. The
confidence interval for the Wald estimates were obtained using
an approximation to Fieller’s theorem[66, 98-101].[102]

The SNP specific Wald-estimates were combined using inversevariance

weighting (IVW) with multiplicative random

effects.[103] The IVW approach is asymptotically equivalent to
the two-stage least squares (2SLS) estimate commonly used with
individual-level data and yields comparable causal
estimates.[104, 105]

SNPs were aligned on effect allele, and direction of effect
amended accordingly using allele harmonization.
palindromic SNPs.

There were no

All six SNPs for alanine were available for

CAD and MI.
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Sensitivity analysis
For sensitivity analysis, I used weighted median and MR-Egger
regression.[104] The weighted-median is robust even in the event
of some violations to the IV assumptions. This method provides a
consistent estimate if at least 50% of the weight comes from
valid IVs.[104] In simulation studies, the weighted-median
estimation method produces similar point estimates, narrower
confidence intervals and better finite-sample Type 1 error rates
than IVW and the 2SLS method.[104]

The MR-Egger method uses a different, still untestable set of
assumptions.[104] MR-Egger regression performs well even when
100% of the IVs are invalid.[104] The slope coefficient from the
Egger regression method provides an estimate of the causal
effect that is consistent asymptotically even if all the genetic
variants have pleiotropic effects on the outcome; but assumes
the inSiDe assumption— (instrument strength independent of
direct effect). A stronger genetic variant should have more
reliable estimates of the causal effect than a weaker variant.
Once the average pleiotropic effect of variants is accounted for
through the intercept term in Egger regression, any residual
dose–response relationship in the genetic associations provides
evidence of a causal effect. A non-null intercept from MR-Egger
indicates an invalid IVW estimate.
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Analysis was conducted using the TwoSample MR package version
0.4.14 for R software version 3.5.1, available at
https://github.com/MRCIEU/TwoSampleMR. Analysis was verified
using the MR-base platform version 1.2.1 e646be (05 December
2018), available at http://app.mrbase.org/. This analysis of
publicly available data did not require IRB approval.

Results
Genetic determinants of alanine
One hundred and twenty-six SNPs were identified from GWAS with
p<1x10-5. Of these, 120 SNPs were excluded because they did not
reach genome wide significance (p<5x10-8). Of the remaining six
SNPs, none were in linkage disequilibrium (R 2<0.001). The Fstatistic for SNPs included in the CAD and MI analyses was 56.92
and SNP specific F-statistic ranged from 36.79 to 110.70.[106108]

No palindromic SNPs were included in this analysis, and

all SNPs in the SNP exposure dataset were available in the
outcome dataset, for additional information about the included
SNPs see table 2 in the appendix.
In MR studies obtaining adequate statistical power is frequently
a concern due to the small amount of variation in a phenotypic
trait that is typically explained by genetic variants, which is
addressed by using large samples for the outcome. To achieve the
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widely accepted power of 80% for epidemiological studies a
sample of about 255,000 participants would be needed for CAD and
about 326,553 participants would be needed for MI.[106-108] The
power calculated for these analyses was .66 for CAD with 184,000
participants and .52 for MI with 171,000 participants.[106-108]

Association of genetically determined alanine with CAD risk
Table 1 shows that the unconfounded estimate of one standard
deviation (SD) higher genetically determined alanine was
associated with lower risk for CAD. Using the IVW approach, the
odds of CAD was 0.89 lower among those with genetically
determined higher levels of alanine than those with lower
genetically determined alanine and was statistically significant
(95% confidence interval (CI) (0.80-0.99). Sensitivity analysis
results obtained using the weighted median and MR-Egger
regression method were not statistically significant, but were
similar in direction, as shown in table 1 and figure 1.

Figure

1 shows the Wald estimates for included SNPs individually, as
well as the MR-Egger and IVW regression results for all SNPs
combined. All but one SNP (rs12578760) was found to be
associated with a lower risk of CAD.

The funnel plot in figure

4 does not indicate heterogeneity among the SNPs, however, the
lack of symmetry could be an indication that an invalid SNP was
included.
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Association of genetically determined alanine with MI risk
Table 1 shows that the causal effect of one standard deviation
(SD) higher genetically determined alanine was not associated
with MI. Using the IVW approach, the odds of MI was 0.90 lower
among per SD of alanine (95% CI (0.800-1.015). Sensitivity
analysis results obtained using the weighted median and MR-Egger
regression method were not statistically significant, but were
directionally similar, as shown in table 1 and figure 1.

Figure

1 shows the Wald estimate for included SNPs individually, as
well as the MR-Egger and IVW regression results for all SNPs
combined. All but one SNP were found to be associated with lower
MI.

The funnel plot in figure 4 does not indicate heterogeneity

among the SNPs, however, the lack of symmetry could be an
indication that an invalid SNP was included.
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Figure 1 – Wald ratio for individual SNPs and MR-Egger and IVW
for all SNPs on CAD and MI
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Table 1 MR estimates of the associations of log-transformed
standardized residuals of Alanine with IHD and with MI

Exposure

Outcome

# of
SNPs

Mendelian
Randomization
Method

IVW
CAD

6

Alanine
MI

6

OR

Cochran’s
Q
statistic
P-Value

95% CI

MR-Egger
Intercept
P-Value

0.889 0.795-0.993 0.369

-

0.928 0.807-1.066 -

-

MR-Egger

0.875 0.486-1.578 0.249

0.961

IVW

0.901 0.800-1.015 0.763

-

0.929 0.801-1.076 -

-

0.932 0.530-1.637 0.631

0.911

Weighted
Median

Weighted
Median
MR-Egger

One SNP, rs1260326 was associated with cholesterol and
triglyceride levels, fasting glucose and blood pressure.

The

remaining SNPs had either no known pleiotropic effects or were
associated with factors not associated with heart disease, such
as glaucoma. Table 3 in the appendix shows these relations.
Estimates were similar after excluding rs1260326.

The IVW

estimate remained statistically significant (odds ratio (OR) –
0.848, 95% confidence interval (CI) 0.742-0.969 and the MR-Egger
results were (OR-0.641, 95% CI 0.321-1.281.

The intercept P-

value was 00.479 and the Q-statistic P-value was 0.3468.
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Discussion

This novel study provides unconfounded estimates that alanine is
associated with a lower risk of CAD. Clinical studies have found
that perfusing the heart with alanine after surgery has improved
recovery, and decreased risk of post-operative infection.[89,
90, 109, 110] Furthermore, small studies conducted in athletes
have shown alanine supplementation has led to improved sports
and exercise performance.[52, 53].

This study provides genetic

validation for alanine as a new target of intervention in CAD.

This study has the advantage of using a novel technique which
enables estimates to be made cost-effectively even when no study
including both the exposure and outcome is available. It also
has the advantage of providing unconfounded estimates.

However,

MR has stringent assumptions. First, the relevance assumption
requires that SNPs be strongly associated with the exposure of
interest.[63]

This study used SNPs that were associated with

the exposure at a P-value <5 x10-8.

Second, the independence

assumption requires that SNPs be independent of exposure outcome
confounders.

This would be expected, as genetic makeup is

determined a conception and independently from each other.[64]
Third, the exclusion-restriction assumption requires that the
SNP affects the outcome only via its effect on the risk factor

40

of interest.[63] Known pleiotropy was assessed using
phennoscanner and few associations with known CAD/MI risk
factors were found for the SNPs included in this analysis.[96,
97] However, estimates were similar after pleiotropic SNPs were
excluded.

Unknown pleiotropy was evaluated using MR-Egger

intercept, and found no indication of pleiotropy.

Given the use

of summarized data in two samples, serum alanine levels were not
measured in the sample with the outcome. However, two-sample
instrumental variable analysis is more robust to chance
associations than analysis of a single sample.[26] Despite the
advantages of MR analysis, several limitations warrant mention.

Making inferences from population based genetic studies, one
would be concerned with population stratification; when a
population subgroup experiences different disease and SNP
frequencies resulting in confounded associations in a whole
population study. The exposure and outcome data included people
largely of European descent.

While this study can no assess the

effect of alanine on CAD/MI by subgroup, there is no reason to
think that mechanism by which alanine affects CAD/MI is group
specific.

Canalization, or developmental compensation occurs

when molecular mechanisms compensate for the effect of the
genotype of interest on the outcome of interest.
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Weak instrument bias should not influence results of this study.
All included SNPs reach genome wide significance.

However, a

weak instrument would bias results toward the null.

Non-linear

effects have successfully been identified using MR, but depend
on additional assumptions.
relationship.

I had to assume a linear

Participant overlap may have occurred in this two

sample MR analysis.

However, given the very large sample size

of the exposure and outcome datasets, the bias if any should not
be of major concern. The CAD/MI case-control studies included
are not wholly composed of incident cases.

Therefore

associations may represent survival with CAD and of a MI rather
than prevention of these outcomes. Finally, MR is better at
identifying the direction of effect rather than its magnitude,
though, the entire population is exposed to alanine, making any
effect relevant to population health.

Alanine might protect against CAD. In rats, introducing alanine
in their diets consistently activated the adenosine
monophosphate-activated protein kinase (AMPK) enzyme.[88]

AMPK

is an enzyme found in the body that is activated when nutrients
are low and during exercise.[88] This study also found that in
rat, mouse and human cells introduction of alanine reduced
glucose levels, not via increases of insulin secretion rather
via increased glucose uptake in the liver.[88]
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Chronic beta-alanine supplementation increases muscle carnosine
concentration, subsequently leading to an improved performance
in high-intensity exercise.[52] The mechanisms by which enhanced
muscle carnosine concentrations result in improved exercise
performance need to be refined in detail, with particular focus
on a complex interaction between pH buffering and improved Ca2+
handling.[52] Observational studies and MR studies have clearly
established the positive relationship between calcium and
CAD.[26, 52, 111, 112]

Since the 1980’s the peer-reviewed literature has supported the
potential for alanine to influence some mechanisms related to
CAD and CAD risk factors.[113] The majority of studies exploring
this relationship have been explored in vitro and in animal
studies.[113]

The paucity of population-based peer-reviewed

literature addressing the relationship of alanine with human CAD
suggests little consideration has been given to the relationship
in epidemiological literature.

Alanine is found abundantly in

the musculoskeletal and heart cells.[85, 88, 90, 91, 113-116]
Furthermore, beta-alanine is known to increase muscle carnosine
levels.[35, 36, 52, 53, 85, 113, 116] Observational studies
among athletes have shown that beta-alanine supplementation
improves exercise performance.[52, 53, 113] Carnosine is widely
considered an important anti-glycating agent, potentially
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improving energy metabolism and protein homeostasis.[113]
Improved handling of glycation end products has had promising
results with diabetes complications, a CAD risk factor.[113]
Additionally, carnosine has antioxidative properties, which are
thought to improve heart health.[90, 113]

However, little data

exists regarding alanine promoting antioxidative processes via
carnosine.

Therefore, future research evaluating its

antioxidative potential in humans is warranted. Observational
studies in the early 2000’s energized interest in antioxidants
processes and heart disease.[89, 110, 113]

Subsequent RCTs

concluded that there was little or no benefit of antioxidant
supplementation in reducing cardiovascular risk. It is possible
that the wrong antioxidants or combination of antioxidants, such
as α-tocopherol and β-carotene have been researched.[113, 116]
Other reasons for the failure of these RCTs to confirm the
observational findings are incorrect dosage, synthetic
antioxidants rather than dietary source and selection bias.[113,
116]

Conclusion
This study provides genetic validation that alanine could be a
new target of intervention to prevent the leading cause of
global morbidity and mortality. Alanine can be modified by diet
changes as it is found in red meat and poultry or via dietary
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supplements.

The effects and mechanisms by which beta alanine

impacts health should be further evaluated in experimental and
clinical studies, beyond the existing literature of in vitro and
animal studies.

Appendix
Table 2 Characteristics of the single nucleotide polymorphisms
(SNP) used for genetically determined serum Alanine.

SNPs
rs12578760

Nearest Effect Other
effect
Gene
Allele Allele
RP11C
T
0.07967
96H19.1

Standard
MAF
error

R2

0.01314

0.8539 <0.001

-0.10458 0.00994

0.5895 <0.001

rs1260326

GCKR

C

T

rs149191093

DDX19B

C

T

rs2160387

-

T

C

rs2694917

RBMS2

C

T

0.086007 0.012989 0.2266 <0.001

rs4554975

SLC38A4 A

G

0.009598 0.4294 <0.001
0.069135
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0.024508 0.9632 <0.001
0.161931
0.009603 0.5567 <0.001
0.071001

Table 3 Select Pleiotropic effects of Relevant Alanine SNPs

SNPs

rs12578760

Nearest
Gene
RP1196H19.1

rs1260326

GCKR

rs149191093

DDX19B

rs2160387

-

rs2694917

RBMS2

rs4554975

SLC38A4

Associated Disease
Plateletcrit*
Birth weight of first
child*
Self-reported
glaucoma*
Triglycerides
Plasma lactate
Urate
Total cholesterol
Whole body water mass
C reactive protein
Fasting glucose
Self-reported gout
Platelet count
Sitting height
Plateletcrit
Neutrophil
Reticulocyte
albumin

Associated
Metabolites
Mannose
Serum total
triglycerides
VLDL
Isoleucine

Mannose
Serum total
triglycerides
VLDL
Isoleucine

Pyruvate

Height

Note : * 1x10-5
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2-aminobutyrate
Leucine
Valine
Phenylalanine
Glutamine
Histidine
Threonine
Alanine
Glutamine
ApoA1

Figure 2 – MR Method comparison plot of SNP effect on Alanine
and CAD/MI
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Figure 3 Leave one Alanine SNP out Sensitivity Analysis for CAD
and MI
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Figure 4 - Funnel plot of Relevant SNPs
of the Alanine on CAD and MI Analysis
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to assess heterogeneity
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Paper 2(Glutamine)
Abstract/Summary
Cardiovascular disease (CVD) is the leading cause of death
worldwide. The strong relationship between CVD and lipids has
been well documented in the peer reviewed literature. Little
attention has been given to other, smaller molecular level
dietary components.

Glutamine, a non-essential amino acid and

its effect on Coronary Artery Disease (CAD) have been studied in
animal, observational, in vitro and RCT studies.

These studies

have had mixed findings raising doubt as to the protective
effect of glutamine on CAD/MI.

To clarify we assessed whether

people with genetically higher levels of glutamine had lower
coronary artery disease (CAD) and myocardial infarction (MI)
risk. We used a two sample Mendelian randomization study. five
SNPs strongly associated (genome wide significant) with
glutamine were applied to large extensively genotyped CAD and MI
studies to obtain unconfounded estimates.

A one standard

deviation increased level of glutamine was not statistically
significantly associated with

CAD (OR 1.09, 95% CI 0.99-1.19)

or MI (OR 1.05, 95% CI 0.95-1.16). The sensitivity analysis also
indicated that the IVW estimate might be invalid because the pvalue for the MR-Egger intercept was significant. After removing
pleiotropic SNPs the MR-Egger intercept was no longer
significant.

Our findings are inconsistent with the

observational, in vitro and animal studies findings in the older
existing literature. However, more recently, observational
studies have reported glutamine has atherogenic properties and
two randomized studies found no association between glutamine
and critical illness. These findings raise new questions of the
causal effect of glutamine on CAD/MI.

A harmful effect of

glutamine on CAD cannot be ruled out, future research is needed
to better understand whether glutamine causes CAD.

Introduction

Cardiovascular disease (CVD) is the leading cause of death
worldwide.[1, 2] The World Health Organization (WHO) estimates
that in 2016, 17,900,00 deaths, or 31% of all deaths, were from
CVD.[2] In the United States, about one in four deaths, or
approximately 610,000 deaths, were due to CVDs.[3-5] Coronary
artery disease (CAD) accounted for 42% of all CVD deaths
worldwide, or approximately 7.4 million deaths, while CAD
accounted for about 60% of all CVD deaths in the United States,
or approximately 375,000 deaths.[3, 4, 6-11]

Observational epidemiological studies have identified numerous
risk factors for CAD, including hypertension, hyperlipidemia,
smoking, obesity, diabetes, unhealthy diet, and physical
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inactivity.[12-14] Yet, how these and other

factors combine in

complex causal mechanisms to cause CAD remains poorly
understood.[6, 25-27] Meta-analyses of observational studies do
not always draw the same conclusion about the relationship
between protein consumption and CAD/myocardial infarction
(MI).[29-32] Furthermore, randomized controlled trials
(RCTs)[24] that have identified pharmacotherapies capable of
mitigating CAD risk factors and CAD have had inconsistent
results.[15]

Glutamine is a conditionally-essential amino acid.[39, 40] This
means that under normal circumstances, the body produces the
necessary amount of this amino acid for the biosynthesis of
proteins. However, in conditions such as injury and stress, the
body may require supplementation of the amino acid through
dietary intake.[37] Glutamine is found in a variety of foods,
notably nuts.[49-51] It is commonly found in walnuts and other
nuts.[51] The most prominent glutamine-producing human tissue is
muscle, accounting for the majority of the glutamine produced by
the body.[39]

Glutamine is found in many supplements used by athletes because
it helps signal cell growth and increases water retention in
muscle cells.[34] A 2011 RCT assessed the cardio-protective
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effects of glutamine on patients with CAD following open-heart
surgery.[38] Clinical tests after surgery found that glutamine
improved heart function in the experimental arm.[39] In an
animal trial, researchers reported that post-ischemic
reperfusion of a rat heart with glutamine restored normal
cardiac output.[41] A meta-analysis of 53 RCT studies found
moderate to weak evidence that glutamine supplementation
influences outcomes such as infection and recovery from surgery
and other critical illness. However, it found no effect on the
risk of mortality or length of ICU stay.[39]

The existing literature suggests that glutamine has inconsistent
effects on CVD and CVD-related risk factors. A large RCT with
CAD events as the primary outcome would be definitive, but
costly. Additionally, randomly assigning research participants
to alter amino acid consumption to determine the effect on CAD
would be impractical and difficult to implement, as modifying
diet on a long-term basis presents a compliance challenge, and
the outcome of interest takes decades to develop. It would also
take several years and be difficult to justify with such mixed
evidence of the benefits of glutamine. The potential harmful
effect of glutamine would also make an RCT difficult to justify.
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There remains a considerable opportunity to identify new casual
factors and treatments for CAD/MI. This study will use Mendelian
randomization (MR) to estimate the effects of glutamine on
CAD/MI. MR has several advantages when compared to conventional
observational studies and is being increasingly used because it
overcomes some major limitations of observational study designs,
including unmeasured confounding. MR uses genetic variants as
instrumental variables for modifiable risk factors that affect
population health.[63] The principle underlying MR originates
from the “The Law of Independent Assortment,” also known as
Mendel’s second law, which states that inheritance of one trait
is independent of other traits, thus allowing for the use of
observational data with genetic variants as natural
experiments.[63, 64] Genetic variants, being fixed at
conception, support causal inference by minimizing
confounding.[63] MR studies are not influenced by confounding
due to Mendel’s Law of independent assortment.[60]

Methods

As is the case in all analytic approaches, MR depends on three
assumptions.

The relevance, independence and exclusion

restriction assumptions are key in selecting valid instrumental
variables.

The relevance assumption means that the genetic

4

instruments predict the exposure reliably. The relevance
assumption is assured by selecting single nucleotide
polymorphisms (SNPs) strongly associated with the exposure of
interest from genome-wide association studies (GWAS).[63] The
independence assumption means that the genetic instruments are
not associated with confounders of the exposure outcome
relation. The independence assumption requires the assessment of
SNP effects, to minimize the possibility of confounding.[63, 92]
The exclusion-restriction assumption means that the genetic
instruments are only associated with the outcome via the
exposure. The exclusion restriction assumption is assessed from
biological knowledge of the effects of the genetic instruments,
known associations of the genetic instruments with other factors
and statistical tests for pleiotropy.
Contributed data was corrected for population stratification,
which has been shown to occur even in single ethnicity
populations. Ancestry and the non-random distribution of SNPs
was corrected for using genomic control by adjusting for
principal components.

Genetic associations with glutamine
Genetically determined levels of glutamine were obtained from a
genome-wide association study (GWAS).[93, 94] The Computational
Medicine extended GWAS combined data from 11 genetic studies and
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14 data sources for a total sample size of 24,925 individuals of
European descent (Finland, Estonian, Netherlands and
Germany).[93, 94] The mean age of the study participants was
44.6 years. The individual study average ages ranged from 31.2
to 61.3 years. Women were 55% of the total sample, and
individual study samples ranged from 37% to 64% female.[93, 94]
Single nucleotide polymorphisms (SNPs) strongly and
independently associated with glutamine (p<5x10 -8) were
selected.[93, 94] The MR-Base “clumping” function was used to
identify correlations between the chosen SNPs.[95] SNP effects
on CAD/MI via physiologic pathways other than glutamine
(pleiotropy) were assessed from a comprehensive genotype and
phenotype cross-references, PhenoScanner.[96, 97]

Genetic associations with CAD
Data on CAD/MI were contributed by the CARDIoGRAMplusC4D. Data
were downloaded from www.CARDIOGRAMPLUSC4D.ORG.
CARDIoGRAMplusC4D 1000 Genomes is a CAD and MI case (n=60,801)control (n=123,504) study extensively genotyped using the 1000
Genomes catalog that partially overlaps with CARDIoGRAMplusC4D.
The majority (77%) of the participants were of European
ancestry; 13% and 6% were of South Asian (India and Pakistan)
and East Asian (China and Korea) ancestry, respectively, with
smaller samples of Hispanic and African Americans.
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The mean age

was about 56.9 years, with genetic associations adjusted for
study specific covariates. Phenotyping of CAD, MI or both was
based on medical records, clinical diagnosis, procedures that
indicate CAD, medications or symptoms that indicate angina, or
self-reporting of CAD.

Statistical analysis
Associations of glutamine with CAD/MI were obtained from
separate sample instrumental variable analysis with genetic
instruments. SNP-specific Wald estimates (ratio of SNP on CAD/MI
to SNP on glutamine) of the effect of glutamine on CAD/MI were
obtained. The confidence intervals for the Wald estimates were
obtained using an approximation to Fieller’s theorem.[66, 98102]

The SNP specific Wald-estimates were combined using inversevariance weighting (IVW) with multiplicative random
effects.[103] The IVW approach is asymptotically equivalent to
the two-stage least squares (2SLS) estimate commonly used with
individual-level data and yields comparable causal
estimates.[104, 105]
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Sensitivity analysis
For sensitivity analysis, I used weighted median and MR-Egger
regression.[104] The weighted-median is a robust alternative
even in the event of some violations to the IV assumptions.
Assuming that no single SNP contributes more than 50% of the
weight to the estimate, this method provides a consistent
estimate if at least 50% of the weight comes from valid
IVs.[104] In simulation studies, the weighted-median estimation
method produces similar point estimates, narrower confidence
intervals and better finite-sample Type 1 error rates than IVW
and the 2SLS method.[104]

The MR-Egger method uses a different, still untestable set of
assumptions.[104] MR-Egger regression performs well even when
100% of the IVs are invalid.[104] The slope coefficient from the
Egger regression method provides an estimate of the causal
effect that is consistent asymptotically even if all the genetic
variants have pleiotropic effects on the outcome; this is known
as the inSiDe assumption—instrument strength independent of
direct effect. A stronger genetic variant should have more
reliable estimates of the causal effect than a weaker variant.
Once the average pleiotropic effect of variants is accounted for
through the intercept term in Egger regression, any residual
dose–response relationship in the genetic associations provides
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evidence of a causal effect. A non-null intercept from MR-Egger
indicates an invalid IVW estimate.

Analysis was conducted using the TwoSample MR package version
0.4.14 for R software version 3.5.1, available at
https://github.com/MRCIEU/TwoSampleMR. Analysis was verified
using the MR-base platform version 1.2.1 e646be (05 December
2018), available at http://app.mrbase.org/. This analysis of
publicly available data did not require IRB approval.

Results

Genetic determinants of Glutamine
Forty-four SNPs were identified from GWAS with p<1x10-5. Of
these, 38 SNPs were excluded because they did not reach genome
wide significance (p<5x10-8 ). We attempted to align one
palindromic SNP, rs7952320 using a minor allele frequency (MAF)
of 0.3 but the results were ambiguous.

No proxy SNP was

available and rs7952320 was excluded for both the CAD and MI
analysis. Of the remaining five SNPs, all were available in the
outcome dataset.

The final analysis was limited to the 5 SNPs

available in both datasets. No SNP was in linkage disequilibrium
(R2<0.001). The F-statistic for SNPs included in the CAD and MI
analyses was 91.48 and SNP specific F-statistic ranged from
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31.33 to 314.03.[106-108]For additional information about the
included SNPs see table 2 in the appendix.
In MR studies obtaining adequate statistical power is frequently
a concern due to the small amount of variation in a phenotypic
trait that is typically explained by genetic variants, which is
addressed by using large samples for the outcome. To achieve the
widely accepted power of 80% for epidemiological studies a
sample of about 194,406 participants would be needed for CAD and
about 879,248 participants would be needed for MI.[106-108] The
power calculated for these analyses was .78 for CAD with 184,000
participants and .23 for MI with 171,000 participants.[106-108]

Association of genetically determined glutamine with CAD risk
Table 1 shows the unconfounded estimate of one standard
deviation (SD) higher genetically determined glutamine was not
clearly associated with increased risk for CAD or MI. Using the
IVW approach, the odds of CAD was 1.09 higher per 1 SD increase
in glutamine but was not statistically significant 95%
confidence interval (CI) (0.99-1.19). Sensitivity analysis
results obtained using the weighted median and MR-Egger
regression method were statistically significant, with a similar
odds ratio estimate as the IVW method, as shown in table 1 and
figure 1. The sensitivity analysis also indicated that the IVW
estimate might be invalid because the p-value for the MR-Egger
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intercept was significant. Figure 1 shows the Wald ratio for
included SNPs individually, as well as the MR-Egger and IVW
regression results for all SNPs combined.

The funnel plot in

figure 4 does not indicate heterogeneity among the SNPs,
however, because so few SNPs are included symmetry is difficult
to assess and an invalid SNP may have been included.

The MR-

Egger method is valid even when invalid SNPs are included. The
findings are unclear and do not unequivocally suggest that
genetically determined glutamine is associated with increased
risk of CAD/MI.

Association of genetically determined glutamine with MI risk
Table 1 shows the unconfounded estimate of one standard
deviation (SD) higher genetically determined glutamine was not
associated with increased risk of MI. Using the IVW approach,
the odds of MI were 1.05 higher among those with genetically
determined higher levels of glutamine than those with lower
genetically determined glutamine, and was not statistically
significant 95% CI (0.95-1.16); however, sensitivity analysis
results obtained using the MR-Egger regression method was
statistically significant, and showed increased risk of MI for
genetically determined higher glutamine levels, as shown in
table 1 and figure 1.

MR-Egger also suggested that the IVW

estimate was not valid. Figure 1 shows the Wald ratio for
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included SNPs individually, as well as the MR-Egger and IVW
regression results for all SNPs combined. The funnel plot in
figure 4 does not indicate heterogeneity among the SNPs,
however, the lack of symmetry could be an indication that an
invalid SNP was included.

The MR-Egger method is valid even

when invalid SNPs are included and the findings among all three
MR methods suggest that the possibility that genetically higher
glutamine levels are associated with MI, but are not definitive.
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Figure 1 Wald ratio for individual SNPs and MR-Egger and IVW for
all SNPs on CAD and MI
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Table 1 MR estimates of the associations of log-transformed
standardized residuals of Glutamine with IHD and with MI

Exposure

Outcome

# of
SNPs

Mendelian
Randomization OR
Method

95% CI

Cochran’s
Q
statistic
P-Value

MR-Egger
Intercept
P-Value

0.5682

-

-

-

0.7765

0.014

0.4202

-

-

-

0.7809

0.019

0.99Glutamine

IVW

1.09
1.19

Weighted
CAD

1.00-

5

1.10
Median

1.22
1.01-

MR-Egger

1.21
1.44
0.95-

IVW

1.05
1.16

Weighted
MI

0.96-

5

1.08
Median

1.20
1.00-

MR-Egger

1.21
1.48

Two SNPs, rs1260326 and rs6729711 were associated with
cholesterol and triglyceride levels, fasting glucose and blood
pressure.

The remaining SNPs had either no known pleiotropic

effects or were associated with factors not associated with
heart disease, such as glaucoma. Table 3 in the appendix shows
these relations. Estimates were similar after excluding
rs1260326 and rs6729711.

The IVW estimate CAD was (OR – 1.103,
15

95% CI 0.989-1.231) and the MR-Egger results were (OR- 1.254,
95% CI 1.019-1.543.

The intercept P-value was 0.401 and the Q-

statistic P-value was 0.4602.

Discussion
This novel study does not exclude the possibility that
genetically determined glutamine is associated with an increased
risk of CAD and MI.

The existing literature remains divided on

the direction of effect that glutamine has on CAD.

Research

has suggested supplementing glutamine in critically ill patients
and after surgery reduces infections and mortality rates.[39]
Clinical studies have found that perfusing the heart with
glutamine after surgery has improved recovery, and decreased
risk of post-operative infection.[89, 90, 109, 110] Animal
models have shown that glutamine, but not glutamate or aspartate
improved the cardiac output of rat hearts.[41]

The same study

reported that in a small sample, a single oral dose of glutamine
improved cardiac function on patients with stable angina.[41]
Another study linked glutamine supplements to improved immune
and gastrointestinal function.[37] RCTs have demonstrated that
glutamine supplements improve outcomes in critically ill
patients, including one study that found glutamine was
cardioprotective following cardiopulmonary bypass.[38]

Some RCT

studies have not found that glutamine has any beneficial effects

16

in critically ill patients.[39, 117, 118] Our study does not
clearly suggest that glutamine is a risk factor for CAD and MI.

This study has the advantage of using a novel technique which
enables estimates to be made cost-effectively even when no study
including both the exposure and outcome is available. It also
has the advantage of providing unconfounded estimates.

However,

MR has stringent assumptions. First, the relevance assumption
requires that SNPs be strongly associated with the exposure of
interest.[63]

This study used SNPs that were associated with

the exposure at a P-value <5 x10-8.

Second, the independence

assumption requires that SNPs be independent of exposure outcome
confounders.

This would be expected, as genetic makeup is

determined a conception and independently from each other.[64]
Third, the exclusion-restriction assumption requires that the
SNP affects the outcome only via its effect on the risk factor
of interest.[63] Known pleiotropy was assessed using
phennoscanner and few associations with known CAD/MI risk
factors were found for the SNPs included in this analysis.[96,
97] two SNPs, rs1260326

and rs6729711 are known to also be

associated with cholesterol and triglyceride levels, fasting
glucose and blood pressure.

The remaining SNPs had either no

known pleiotropic effects or were associated with factors not
associated with heart disease, such as hypothyroidism. For
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additional information please see the table 3 in the appendix.
Given the use of summarized data in two samples, serum glutamine
levels were not measured in the sample with the outcome.
However, two-sample instrumental variable analysis is more
robust to chance associations than analysis of a single
sample.[26]

Making inferences from population based genetic studies, one
would be concerned with population stratification[83]; when a
population subgroup experiences different disease and SNP
frequencies resulting in confounded associations in a whole
population study. The exposure and outcome data included people
largely of European descent.

While this study cannot assess the

effect of glutamine on CAD/MI by subgroup, there is no reason to
think that mechanism by which glutamine affects CAD/MI are group
specific.

Canalization, or developmental compensation occurs

when molecular mechanisms compensate for the effect of the
genotype of interest on the outcome of interest.[83]
Weak instrument bias should not influence results of this
study.[83]

All included SNPs reach genome wide significance.

However, a weak instrument would bias results toward the
null.[119]

Non-linear effects have successfully been identified

using MR, but depend on additional assumptions.
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I had to assume

a linear relationship in this analysis.

Participant overlap may

have occurred in this two sample MR analysis.

However, given

the very large sample size of the exposure and outcome datasets,
the bias if any should not be of major concern.[26, 120, 121]
Finally, MR is better at identifying the direction of effect
rather than its magnitude, though, the entire population is
exposed to glutamine, making any effect relevant to population
health.
The role of glutamine in CAD and MI remains unclear.

Studies

have found glutamine a reliable discriminator of CAD and non-CAD
among cardiac catheterization patients.[114, 122] Glutamine has
also been found to be associated with plaque development and
intima–media thickness.[114, 115, 123] Some in vitro and animal
studies have found that glutamine levels have been associated
with atherosclerosis and CAD risk. [114]
the accumulation of triglycerides

Glutamine stimulates

in microphages by affecting

the SREBP-1, a key regulator in cellular triglyceride
biosynthesis.[114] Furthermore, glutamine stimulates microphage
oxidative stress, affecting lipid metabolism.[114]

Conclusion
This study found glutamine had no statistically significant
relationship with CAD or MI. It is possible that a study with
higher power would have detected a small increased risk of CAD
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and MI in individuals with genetically determined higher
glutamine.

Glutamine can be modified by diet changes as it is

found in nuts and red meat or via dietary supplements. The
literature has hypothesized several biological mechanisms by
which glutamine effects CAD and MI.

The effect on CAD should be

conclusively evaluated in a larger MR study to assess glutamine
as a risk factor for CAD and MI.

Appendix
Table 2 Characteristics of the single nucleotide polymorphisms
(SNP) used for genetically determined serum glutamine.
SNPs

Nearest
Gene
RP11-

rs12306007

Effect Other
effect
Allele Allele

Standard
MAF
error

R2

T

C

0.079358 0.013439 0.860 <0.001
0.061666 0.010082 0.361 <0.001

96H19.1
rs1260326

GCKR

C

T

rs2657879

DDX19B

G

A

0.012494 0.824 <0.001
0.221406
rs6729711

-

A

G

0.01243

0.819 <0.001

0.069575
rs7078003

RBMS2

T

C

0.073854 0.011712 0.804 <0.001

rs7952320

SLC38A4

C

G

0.053765 0.009369 0.466 <0.001
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Table 3 Select Pleiotropic effects of Relevant Glutamine SNPs
SNPs
rs12306007

rs1260326

rs2657879

Nearest

Gene

Associated Disease

Birth weight of
chr12:46790259 first child
Height
Triglycerides
Plasma lactate
Urate
Total cholesterol
Whole body water
mass
C reactive protein
GCKR
Fasting glucose
Self-reported gout
Platelet count
Sitting height
Plateletcrit
Neutrophil
Reticulocyte
albumin
GLS2

Fasting glucose

rs6729711

AC005540.3

Mean platelet volume
Height*
reticulocyte count*
hypothyroidism*
myxedema*
Pulse rate*
Diastolic blood
pressure*

rs7078003

RP11-548K23.11

Note : * 1x10-5
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Associated
Metabolites
-

Mannose
Serum total
triglycerides
VLDL
Isoleucine

Figure 2 MR Method comparison plot of SNP effect on Alanine and
CAD/MI
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Figure 3 Leave one Glutamine SNP out Sensitivity Analysis for
CAD and MI
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Figure 4 Funnel plot of Relevant SNPs to assess heterogeneity of
the Glutamine on CAD and MI Analysis
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Paper 3(Glycine)
Abstract/Summary
Cardiovascular disease (CVD) is the leading cause of death
worldwide. CVD is poorly understood.

Some attention has been

given in the literature to the cardioprotective effects glycine
has in humans.

The relationship has primarily been explored in

clinical and animal models.

Few large observational studies

have explored the effect of glycine on heart disease.

To

clarify we assessed whether people with genetically higher
levels of glycine had lower coronary artery disease (CAD) and
myocardial infarction (MI) risk. We used a two sample Mendelian
randomization study. Six SNPs strongly associated (genome wide
significantly) with glycine were applied to large extensively
genotyped CAD and MI studies to obtain unconfounded estimates.
A one standard deviation increase in genetically determined
glycine was associated with lower risk of

CAD (odds ratio (OR)

0.94, 95% confidence interval (CI) 0.91-0.98) but not MI (OR
0.97, 95% CI 0.93-1.02). Sensitivity analysis indicated that the
IVW estimate might be invalid because of pleiotropy (significant
p-value for the MR-Egger intercept). After removing pleiotropic
SNPs the MR-Egger intercept was no longer significant. These
findings cannot rule out the possibility that glycine is
cardioprotective and raises new questions of the causal effect

of glycine on CAD/MI.

Future research is needed to better

understand whether glycine influences CAD.
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Introduction
Cardiovascular disease (CVD) are the leading cause of death
worldwide.[1, 2] The World Health Organization (WHO) estimates
that in 2016, 17,900,00 deaths, or 31% of all deaths, were from
CVD.[2] In the United States, about one in four deaths, or
approximately 610,000 deaths, were due to CVDs.[3-5] Coronary
artery disease (CAD) accounted for 42% of all CVD deaths
worldwide, or approximately 7.4 million deaths, while CAD
accounted for about 60% of all CVD deaths in the United States,
or approximately 375,000 deaths.[3, 4, 6-11]

Observational epidemiological studies have identified numerous
risk factors for CAD, including hypertension, hyperlipidemia,
smoking, obesity, diabetes, unhealthy diet, and physical
inactivity.[12-14] Yet, how these and other factors combine in
complex causal mechanisms to cause CAD remains poorly
understood.[6, 25-27] Meta-analyses of observational studies do
not always draw the same conclusion about the relationship
between protein consumption and CAD/myocardial infarction
(MI).[29-32] Furthermore, randomized controlled trials
(RCTs)[24] that have tested pharmacotherapies capable of
mitigating CAD risk factors have had inconsistent effects on
CAD.[15]

2

Glycine is a conditionally-essential amino acid.[39, 40] This
means that under normal circumstances, the body produces the
necessary amount of this amino acid for the biosynthesis of
proteins. However, in conditions such as injury and stress, the
body may require supplementation of the amino acid through
dietary intake.[37] Glycine is most notably found in gelatin and
is a major component of collagen, which is abundant in blood
vessels and the gut, among other fibrous tissues.[36, 40, 42,
55, 56]

Glycine is an amino acid involved in anti-oxidative reactions
and collagen formation.[56] Many studies have shown an inverse
association of glycine with hypertension and type two
diabetes.[42] A 2016 clinical study assessed the relationship of
plasma glycine and acute MI. The authors reported that glycine
was inversely associated with the risk of MI.[56] They found a
stronger association in patients with apolipoprotein B, low
density lipoprotein cholesterol, or apolipoprotein A-1 above the
median.[56] Other studies have reported the positive effects of
glycine on vascular health.[42] Glycine has been reported to
stabilize platelets, reduce the sizes of areas of ischemic
injury upon reperfusion, correct elevated blood pressure and
normalize serum triglycerides.[55, 56] While these studies in
rats and humans reported an inverse relationship with glycine
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and CAD or CAD-related risk factors, none estimated a causal
relationship or the underlying pathway by which glycine reduces
CAD or its related risk factors.

The existing literature is consistent but inconclusive about the
effects glycine has on CVD and CVD-related risk factors. A large
RCT with CAD events as the primary outcome would be definitive,
but costly. Additionally, randomly assigning research
participants to alter amino acid consumption to determine the
effect on CAD would be impractical and difficult to implement,
as modifying diet on a long-term basis presents a compliance
challenge, and the outcome of interest takes decades to develop.
It would also take several years and be difficult to justify
with limited evidence of the benefits of glycine.

A recent study published by Wittemans, Laura B. L. et.al. in
Nature Communications used MR to estimate the causal
relationship of glycine with CAD, CAD risk factors and
diabetes.[124]

The researchers make a compelling case for the

cardioprotective effect of glycine on CAD.[124]

They also make

a case for systolic and diastolic blood pressure as a mediator
between glycine and CAD.[124]
mention.

Several differences warrant

The study sample used in the recently published study

expanded on the exposure sample used in our study but may have
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been affected by heterogeneity between studies due to
differences metabolomics platforms and in analytical decisions
between the studies, such as transformation of the glycine
measures and inclusion of covariates.[124-126] The SNP exposure
estimates in the previously published study were adjusted for
age, sex and the first 10 principal components, while my study
only adjusted for the first 4 principal components.[79, 93, 94,
124] Thus, raising a question about overfitting the SNP exposure
model.

The recently published paper developed sex specific

models adjusting for several covariates, including age, sex,
genotyping array, testing center and the first 4 principal
components.

Sex combined associations made no such adjustments.

Our study also makes no such adjustments in the SNP outcome
estimates.[79, 93, 94, 124]

However, the recently published

paper used a weighted median regression MR analysis, while our
study used IVW MR analysis as the main analysis.

Weighted

median regression analysis was used only as a sensitivity
analysis in our study.

Weighted median MR is an

overidentification method that assume the instrumental variable
assumptions hold for some of the genetic variants, but not
necessarily for all genetic variants.[105, 125-129]

Median-

based methods may suggest a positive causal effect despite
evidence for directional pleiotropy as a result of the relaxed
assumptions.[105, 125-129]

One issue with down-weighting is
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that giving less weight to Wald estimates that deviate
significantly from the majority and standard error of the causal
effect estimate will be reduced after down weighting those SNPs
that appear to deviate from the majority.[105, 125-129] This can
be particularly problematic when no sound biologically plausible
reason justifies such down weighting as the down-weighted
outlier may be the most biologically reasonable.[105, 125-129]

There remains a considerable opportunity to identify new
casual factors and treatments for CAD/MI. This study will use
Mendelian randomization (MR) to estimate the effects of glycine
on CAD/MI. MR has several advantages when compared to
conventional observational studies and is being increasingly
used because it overcomes some major limitations of
observational study designs, including unmeasured confounding.
MR uses genetic variants as instrumental variables for
modifiable risk factors that affect population health.[63] The
principle underlying MR originates from the “The Law of
Independent Assortment,” also known as Mendel’s second law,
which states that inheritance of one trait is independent of
other traits, thus allowing for the use of observational data
with genetic variants as natural experiments.[63, 64] Genetic
variants, being fixed at conception, support causal inference by
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minimizing confounding.[63] MR studies are not influenced by
confounding due to Mendel’s Law of independent assortment.[60]
Methods
As is the case in all analytic approaches, MR depends on three
assumptions.

The relevance, independence and exclusion

restriction assumptions are key in selecting valid instrumental
variables.

The relevance assumption means that the genetic

instruments predict the exposure reliably. The relevance
assumption is assured by selecting single nucleotide
polymorphisms (SNPs) strongly associated with the exposure of
interest from genome-wide association studies (GWAS).[63] The
independence assumption means that the genetic instruments are
not associated with confounders of the exposure outcome
relation. The independence assumption requires the assessment of
SNP effects, to minimize the possibility of confounding.[63, 92]
The exclusion-restriction assumption means that the genetic
instruments are only associated with the outcome via the
exposure. The exclusion restriction assumption is assessed from
biological knowledge of the effects of the genetic instruments,
known associations of the genetic instruments with other factors
and statistical tests for pleiotropy.
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Genetic associations with glycine
Genetically determined levels of glycine were obtained from a
genome-wide association study (GWAS).[93, 94] The Computational
Medicine extended GWAS combined data from 11 genetic studies and
14 data sources for a total sample size of 24,925 individuals of
European descent (Finland, Estonian, Netherlands and
Germany).[93, 94] The mean age of the study participants was
44.6 years. The individual study average ages ranged from 31.2
to 61.3 years. Women were 55% of the total sample, and
individual study samples ranged from 37% to 64% female.[93, 94]
Single nucleotide polymorphisms (SNPs) strongly and
independently associated with glycine (p<5x10 -8) were
selected.[93, 94] The MR-Base “clumping” function was used to
identify correlations between the chosen SNPs.[95] SNP effects
on CAD/MI via physiologic pathways other than glycine
(pleiotropy) were assessed from a comprehensive genotype and
phenotype cross-references, PhenoScanner.[96, 97]
Contributed data was corrected for population stratification,
which has been shown to occur even in single ethnicity
populations. Ancestry and the non-random distribution of SNPs
was corrected for using genomic control by adjusting for
principal components.
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Genetic associations with CAD
Data on CAD/MI were contributed by the CARDIoGRAMplusC4D. Data
were downloaded from www.CARDIOGRAMPLUSC4D.ORG.
CARDIoGRAMplusC4D 1000 Genomes is a CAD and MI case (n=60,801)control (n=123,504) study extensively genotyped using the 1000
Genomes catalog that partially overlaps with CARDIoGRAMplusC4D.
The majority (77%) of the participants were of European
ancestry; 13% and 6% were of South Asian (India and Pakistan)
and East Asian (China and Korea) ancestry, respectively, with
smaller samples of Hispanic and African Americans.

The mean age

was about 56.9years, with genetic associations adjusted for
study specific covariates. Phenotyping of CAD, MI or both was
based on medical records, clinical diagnosis, procedures that
indicate CAD, medications or symptoms that indicate angina, or
self-reporting of CAD.

Statistical analysis
Associations of glycine with CAD/MI were obtained from separate
sample instrumental variable analysis with genetic instruments.
SNP-specific Wald estimates (ratio of SNP on CAD/MI to SNP on
glycine) of the effect of glycine on CAD/MI were obtained. The
confidence interval for the Wald estimates were obtained using
an approximation to Fieller’s theorem.[66, 98-102]
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The SNP specific Wald-estimates were combined using inversevariance weighting (IVW) with multiplicative random
effects.[103] The IVW approach is asymptotically equivalent to
the two-stage least squares (2SLS) estimate commonly used with
individual-level data and yields comparable causal
estimates.[104, 105]

Sensitivity analysis
For sensitivity analysis, I used weighted median and MR-Egger
regression.[104] The weighted-median is a robust alternative
even in the event of some violations to the IV assumptions.
Assuming that no single SNP contributes more than 50% of the
weight to the estimate, this method provides a consistent
estimate if at least 50% of the weight comes from valid
IVs.[104] In simulation studies, the weighted-median estimation
method produces similar point estimates, narrower confidence
intervals and better finite-sample Type 1 error rates than the
IVW and the 2SLS method.[104]

The MR-Egger method uses a different, still untestable set of
assumptions.[104] MR-Egger regression performs well even when
100% of the IVs are invalid.[104] The slope coefficient from the
Egger regression method provides an estimate of the causal
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effect that is consistent asymptotically even if all the genetic
variants have pleiotropic effects on the outcome; this is known
as the inSiDe assumption—instrument strength independent of
direct effect. A stronger genetic variant should have more
reliable estimates of the causal effect than a weaker variant.
Once the average pleiotropic effect of variants is accounted for
through the intercept term in Egger regression, any residual
dose–response relationship in the genetic associations provides
evidence of a causal effect. A non-null intercept from MR-Egger
indicates an invalid IVW estimate.

Analysis was conducted using the TwoSample MR package version
0.4.14 for R software version 3.5.1, available at
https://github.com/MRCIEU/TwoSampleMR. Analysis was verified
using the MR-base platform version 1.2.1 e646be (05 December
2018), available at http://app.mrbase.org/. This analysis of
publicly available data did not require IRB approval.

Results
Genetic determinants of glycine
Six SNPs identified reached genome wide significance (p<5x10 -8).
All six SNPs found for the exposure were available for the
outcome.

One palindromic SNP, rs147007805, was aligned using

the minor allele frequency (MAF).
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The MAF threshold was set to

0.3. No SNP was in linkage disequilibrium (R 2<0.001).

The F-

statistic for SNPs included in the CAD and MI analyses was
376.75 and SNP specific F-statistic ranged from 33.31 to
1927.22.[106-108]
In MR studies obtaining adequate statistical power is frequently
a concern due to the small amount of variation in a phenotypic
trait that is typically explained by genetic variants, which is
addressed by using large samples for the outcome. In a sample
size of 184,000, assuming the genetic variants explain 2% of the
variance in glycine, then this study had 80% power to detect an
OR of 0.907 [106-108]

Association of genetically determined glycine with CAD risk
Table 1 shows the unconfounded estimate of one standard
deviation (SD) higher genetically determined glycine was
associated with decreased risk of CAD. Using the IVW approach,
the odds of CAD was 0.94 per 1 SD increase in glycine 95% CI
(0.91-0.98). Sensitivity analysis results obtained using the
weighted median and MR-Egger produced similar estimates as the
IVW method, as shown in table 1 and figure 1. Figure 1 shows the
Wald estimate for each included SNP individually, as well as the
MR-Egger and IVW regression results for all SNPs combined.
However, the p-value for the MR-Egger intercept was significant
suggesting that the IVW estimate is invalid.
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The funnel plot in figure 4 does not indicate heterogeneity
among the SNPs, however, because so few SNPs are included
symmetry is difficult to assess and an invalid SNP may have been
included.

Association of genetically determined glycine with MI risk
Table 1 shows that the effect of one standard deviation (SD)
higher genetically determined glycine was not clearly associated
with decreased risk of MI. Using the IVW approach, the odds of
MI were 0.97 lower among those with genetically determined
higher levels of glycine than those with lower genetically
determined glycine, and was not statistically significant 95% CI
(0.93-1.02). Furthermore, sensitivity analysis results obtained
using the MR-Egger regression method were not statistically
significant, and produced similar estimates of no association
between MI and genetically determined levels of glycine, as
shown in table 1 and figure 1. However, the p-value for the MREgger intercept was significant suggested that the IVW estimate
is invalid.

Figure 1 shows the Wald estimate for included SNPs individually,
as well as the MR-Egger and IVW regression results for all SNPs
combined. The funnel plot in figure 4 does not indicate

13

heterogeneity among the SNPs, however, the lack of symmetry
could be an indication that an invalid SNP was included.
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Figure 1 Wald ratio for individual SNPs and MR-Egger and IVW for
all SNPs on CAD and MI
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Table 1 MR estimates of the associations of log-transformed
standardized residuals of Glycine with IHD and with MI
# of
Exposure Outcome
SNPs

Mendelian
Randomization OR
Method

Glycine

IVW

0.94

Weighted
Median

0.95

MR-Egger

0.97

IVW

0.97

Weighted
Median

0.97

MR-Egger

1.00

CAD

MI

95% CI
0.9050.980
0.910.99
0.911.03
0.931.02
0.941.07
0.941.07

Cochran’s
MR-Egger
Q
Intercept
statistic
P-Value
P-Value
0.8743

-

-

-

0.9685

- 0.0096

0.5967

-

-

-

0.7456

-0.013

Two SNPs, rs1047891 and rs2169387 were associated with
cholesterol and triglyceride levels, fasting glucose and blood
pressure.

The remaining SNPs had either no known pleiotropic

effects or were associated with factors not associated with
heart disease, such as glaucoma. Table 3 in the appendix shows
these relations. Estimates were similar after excluding
rs1047891 and rs2169387.

The IVW estimate CAD was (OR – 0.8861

, 95% CI 0.788-0.996) and the MR-Egger results were (OR- 0.8772
, 95% CI 0.771 0.998).

The intercept P-value was 0.569 and the

Q-statistic P-value was 0.8893.
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Discussion
This novel study does not exclude the possibility that
genetically determined glycine is associated with a lower risk
of CAD. Glycine is most notably found in gelatin and is a major
component of collagen, which is abundant in blood vessels and
the gut, among other fibrous tissues.[36, 40, 42, 55, 56]
Glycine is part of the human diet, with the highest
concentrations found in shellfish, white fish, pork, turkey and
chicken skin as well as soybeans.[130]
Studies, including in vitro, animal and human observational
studies have shown an inverse association of glycine with CAD
and CAD risk factors.[42] A 2016 RCT found that glycine was
inversely associated with the risk of MI.[56] a stronger
protective effect was found in patients with a level of
apolipoprotein B, low density lipoprotein cholesterol, or
apolipoprotein A-1 above the median.[56] Other studies have
reported positive effects of glycine on vascular health.[42]
Glycine has been reported to stabilize platelets, reduce the
sizes of areas of ischemic injury upon reperfusion, correct
elevated blood pressure and normalize serum triglycerides.[55,
56]

This study has the advantage of using a novel technique which
enables estimates to be made cost-effectively even when no study
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including both the exposure and outcome is available. It also
has the advantage of providing unconfounded estimates.

However,

MR has stringent assumptions. First, the relevance assumption
requires that SNPs be strongly associated with the exposure of
interest.[63]

This study used SNPs that were associated with

the exposure at a P-value <5 x10-8.

Second, the independence

assumption requires that SNPs be independent of exposure outcome
confounders.

This would be expected, as genetic makeup is

determined a conception and independently from each other.[64]
Third, the exclusion-restriction assumption requires that the
SNP affects the outcome only via its effect on the risk factor
of interest.[63] Known pleiotropy was assessed using
Phenoscanner and few associations with known CAD/MI risk factors
were found for the SNPs included in this analysis.[96, 97] Two
SNPs, rs1047891

and rs2169387 are known to also be associated

with cholesterol and triglyceride levels, fasting glucose and
blood pressure.

The remaining SNPs had either no known

pleiotropic effects or were associated with factors not
associated with heart disease, such as height. For additional
information please see the table 3 in the appendix.

Given the

use of summarized data in two samples, serum glycine levels were
not measured in the sample with the outcome. However, two-sample
instrumental variable analysis is more robust to chance
associations than analysis of a single sample.[26]
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Making inferences from population based genetic studies, one
would be concerned with population stratification[83]; when a
population subgroup experiences different disease and SNP
frequencies resulting in confounded associations in a whole
population study. The exposure and outcome data included people
largely of European descent.

While this study cannot assess the

effect of glycine on CAD/MI by subgroup, there is no reason to
think that mechanism by which glycine affects CAD/MI are group
specific.

Canalization, or developmental compensation occurs

when molecular mechanisms compensate for the effect of the
genotype of interest on the outcome of interest.[83]
Weak instrument bias should not influence results of this
study.[83]

All included SNPs reach genome wide significance.

However, a weak instrument would bias results toward the
null.[119]

Non-linear effects have successfully been identified

using MR, but depend on additional assumptions.
a linear relationship in this analysis.

I had to assume

Participant overlap may

have occurred in this two sample MR analysis.

However, given

the very large sample size of the exposure and outcome datasets,
the bias if any should not be of major concern.[26, 120, 121]
Finally, MR is better at identifying the direction of effect
rather than its magnitude, though, the entire population is
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exposed to glycine, making any effect relevant to population
health.
Glycine may be associated with a decreased risk of

CAD.

There

has been evidence since as far back as the 1970’s that that the
levels of myocardial glycine metabolism change due to myocardial
ischemia.[34] Glycine is known to stimulate the release of
insulin from the pancreas, and affects glucose homeostasis.[43]
Glycine is also been shown to modulate concentrations of nitric
oxide, a vasodilator; and in at least one study it was
associated with improved blood pressure.[115, 131] However,
observational studies have mixed findings.

The INTERMAP study

showed and inverse relationship of glycine and blood pressure,
and the Rotterdam study found no significant associations
between the two.[115, 132, 133]

A recent study evaluated the

effect of glycine on atherogenesis using murine
macrophages.[114]

Glycine showed clear anti-atherogenic

effects, by significantly reducing macrophage triglyceride
content, related to decreased VLDL uptake.[114] Glycine was the
only amino acid that attenuated both the uptake of the
triglyceride-rich VLDL and the triglyceride biosynthesis rate in
macrophages.[114] there is some evidence that the effect glycine
has on CVD differs by sex.

A 2016 study found that there was an

inverse relationship between glycine and acute MI and was more
favorable among women than men.[134]
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Several biological

pathways have been hypothesized explaining the potential
positive effect that glycine has on CAD, including increasing
intracellular antioxidants, thus having a positive effect on
vascular health. Glycine intake counteracts many of the adverse
effects of a high-sucrose diet on the liver, adipose mass and
vascular function in rats.[55]

Glycine decreased the fatty acid

content of the liver of sucrose-fed rats, corrected an elevation
of blood pressure, normalized the serum triglycerides and
insulin, and, in the vasculature, boosted glutathione, decreased
oxidative stress and normalized endothelium-dependent
vasodilation.[55]

Glycine may stimulate

and glucagon release

and decrease membrane polarization in cells.[55] This may be why
when glucose was fed to patients with type 2 diabetes in
conjunction with gelatin it strengthened the insulin
response[55] Clinically, glp-1 agonist drugs promote modest
weight loss in patients, and exert favorable effects on systolic
blood pressure, serum lipids, inflammatory markers and
endothelial function.[55]
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Conclusion
This study does not exclude the possibility that genetically
determined glycine is associated with a lower odd of CAD.[46] We
replicate a similar study conducted by Wittemans, Laura B. L.
et.al. in Nature Communications that used MR to estimate the
causal relationship of glycine with CAD, CAD risk factors and
diabetes.[124].

Although both studies conducted a MR of glycine

on cardiovascular disease Several differences exist between the
two, including the use of different MR methods, population
sizes, outcomes and homogeneity.

The recently published MR

study found glycine to be cardioprotective.[124]

That same

study found that the protective effect of glycine on CAD was
mediated via improved blood pressure.[124]

Glycine is generally found in the skin, bones and organs of some
animals.

Because most people do not eat these parts of an

animal, glycine can be modified via dietary supplements along
with what is part of a normal diet.

Additional research is

needed to conclusively establish glycine is statistically
significantly associated with lower risk of CAD, and via what
mechanisms glycine affects CAD.
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Appendix
Table 2 Characteristics of the single nucleotide polymorphisms
(SNP) used for genetically determined serum glycine.

Nearest

Effect Other

SNPs

Standard
effect

MAF

Gene

Allele Allele

error

rs10083777

CENPN

T

C

-0.10606 0.01

0.827109

rs1047891

CPS1

A

C

0.487116 0.01

0.666106

rs13298772

KIAA2026

C

T

0.273079 0.02

0.946912

rs147007805

MAP2

A

T

-0.14046 0.02

0.925411

rs1992855

ALDH1L1

C

T

0.061971 0.01

0.590467

G

A

-0.13006 0.02

0.13332

RP11rs2169387
115J16.1
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R2

Table 3 Select Pleiotropic effects of Relevant Glycine SNPs

SNPs

Nearest
Gene

rs10083777

CENPN

rs1047891

CPS1

rs13298772

KIAA2026

rs147007805

MAP2

rs1992855

ALDH1L1

rs2169387

RP11115J16.1

Associated Disease

Homocysteine
Whole body water mass
Trunk fat-free mass
Creatinine
Platelet
Chronic kidney
disease
Weight
Illnesses of mother:
heart disease
Hemoglobin
Plateletcrit
Homocysteine
Fibrinogen
Hip circumference
Self-reported
hypertension
Self-reported
migraine
Chronic kidney
disease
Impedance of arm
right
Impedance of whole
body

Associated
Metabolites

Homoarginine
Betaine
Sarcosine
Guanidinosuccinate
Serine
Histidine
Glutamylalanine
Arginine
Creatinine
Threonine

Glycine*
Serine*
Heel bone mineral
density
LDL cholesterol
Neutrophil count
Granulocyte count
Neuroticism
Illnesses of father:
heart disease*
Irritability*

Note : * 1x10-5
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Free cholesterol in
medium HDL
Acetoacetate
3Lhydroxybutyrate
ApoA1

Figure 2 Leave one Glycine SNP out Sensitivity Analysis for CAD
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Figure 3 Plots of SNPs on glycine against SNPs on CAD/MI
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Figure 4 Funnel plot of Relevant SNPs
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Conclusion(overall)

Observational epidemiologic studies are susceptible to
confounding and selection bias.[103, 135] The strength of a
Mendelian randomization (MR) analysis is that it leverages the
natural randomization that is inherent in the assignment of
genetic information at birth increasing the robustness of causal
inference.[103, 135] Observational studies and RCTs have
contributed to the reduction of CHD and MI that has occurred in
western settings in recent decades. Despite these improvements,
cardiovascular diseases, including CHD and MI remain the leading
causes of death.[60] Opportunity remains to identify new casual
factors and treatments for CAD/MI.

This study used MR to

estimate the effects of three amino acids on CAD/MI.

This study is the first MR study to assess the relationship of
CAD/MI with alanine and glutamine. This study also replicates an
analysis of CAD/MI with glycine, strictly adhering to the MR
assumptions. After an extensive literature review, it was
hypothesized that alanine, glutamine and glycine would all have
a cardioprotective effect. Glutamine, glycine, and alanine have
been established in animal studies to be linked with heart
function and heart disease.[34-36, 40-42, 45-48]

Glutamine is

commonly found in nuts, which observational studies and RCTs

have found to be cardio-protective.[44, 49-51] Animal model and
small RCT studies have found that glutamine improves
postoperative outcomes and restores the heart to normal function
more quickly than without glutamine supplements.[38, 47, 48]
Similarly, glycine studies have shown an inverse relationship
with CAD and CAD risk factors such as hypertension. Alanine
studies have shown an inverse relationship with diabetes, a risk
factor for CAD, in light of the beneficial role that alanine
plays in glucose homeostasis and the increased alanine observed
during cardiac events.[52-54]

Alanine
Analysis in this dissertation found that alanine might lower the
risk of CAD.

The unconfounded estimate of one standard

deviation (SD) higher genetically determined alanine was
associated with lower risk. Using the IVW approach, the odds of
CAD was 0.89 lower among those with genetically determined
higher levels of alanine than those with lower genetically
determined alanine and was statistically significant (95%
confidence interval (CI) (0.80-0.99)and the odds of MI was 0.90
lower per SD increase of alanine (95% CI (0.800-1.015).
Sensitivity analysis results obtained using the weighted median
and MR-Egger regression method were not statistically

1

significant, though the effect was in the same protective
direction as was found in the IVW method for both CAD and MI.
Beta-alanine is known to increase muscle carnosine levels.[35,
36, 52, 53, 85, 113, 116] Carnosine is widely considered an
important anti-glycating agent, potentially improving energy
metabolism and protein homeostasis.[113]

Improved handling of

glycation end products has had promising results with diabetes
complications, a CAD risk factor.[113] Additionally, carnosine
has antioxidative properties, which are thought to improve heart
health.[90, 113]
Glutamine
Analysis in this dissertation found that one standard deviation
(SD) higher genetically determined glutamine was not clearly
associated with CAD or MI. Using the IVW approach, the odds of
CAD was 1.09 higher per 1 SD increase in glutamine but was not
statistically significant 95% confidence interval (CI) (0.991.19) and the odds of MI was 1.05 higher per one SD increase in
glutamine but was not statistically significant 95% confidence
interval (CI) (0.99-1.19). Sensitivity analysis results obtained
using the weighted median and MR-Egger regression method were
statistically significant for both CAD and MI, with a similar
odds ratio estimate as the IVW method.

The sensitivity analysis

also indicated that the IVW estimate for CAD and MI might be

2

invalid because the p-value for the MR-Egger intercept was
significant.

The role of glutamine in CAD and MI is unclear.

A study

found

glutamine a reliable discriminator of CAD and non-CAD among
cardiac catheterization patients.[114, 122] Glutamine has also
been associated with plaque development and intima–media
thickness.[114, 115, 123] Some in vitro and animal studies have
found that glutamine levels have been associated with
atherosclerosis and CAD risk. [114]

Glutamine stimulates the

accumulation of triglycerides in microphages by affecting the
SREBP-1, a key regulator in cellular triglyceride
biosynthesis.[114] Furthermore, glutamine stimulates microphage
oxidative stress, affecting lipid metabolism.[114]

The

direction of effect that glutamine has on CAD and MI remains
unclear and should be conclusively evaluated in a large RCT
study to confirm that glutamine is a risk factor for CAD and MI.
Glycine
Analysis in this dissertation found that one standard deviation
(SD) higher genetically determined glycine
was not clearly associated with increased risk for CAD or MI.
Using the IVW approach, the odds of CAD was 0.94 per 1 SD
increase in glycine 95% CI (0.91-0.98) and odds of MI was 0.97
lower among those with genetically determined higher levels of

3

glycine and was not statistically significant 95% CI (0.931.02). Sensitivity analysis results produced similar estimates
however, the p-value for the MR-Egger intercept was significant
suggesting that the IVW estimate is invalid.

Glycine may protect against CAD. Several biological pathways
have been hypothesized explaining the potential positive effect
that glycine has on CAD, including increasing intracellular
antioxidants. Glycine intake counteracts many of the adverse
effects of a high-sucrose diet on the liver, adipose mass and
vascular function in rats and decreased the fatty acid content
of the liver of sucrose-fed rats, corrected an elevation of
blood pressure, normalized the serum triglycerides and insulin,
and, in the vasculature, boosted glutathione, decreased
oxidative stress and normalized endothelium-dependent
vasodilation.[55]

Glycine may stimulate

and glucagon release

and decrease membrane polarization in cells.[55] This may be why
when glucose was fed to patients with type 2 diabetes in
conjunction with gelatin it strengthened the insulin
response[55] This analysis replicates the study conducted by
Wittemans, Laura B. L. et.al., but uses IVW rather than a
weighted median approach to obtain unconfounded estimates.[124]
The IVW method strictly adheres to the assumptions required of a
valid MR analysis, possibly explaining the difference in the

4

significance of the effect observed in the two analyses.

The

recently published MR study found glycine to be
cardioprotective.[124]

My analysis could not rule out the

possibility of a cardioprotective effect, however additional
research is needed to conclusively establish glycine as
cardioprotective, and via what mechanisms glycine affects heart
disease.

Limitations
This study has several limitations.

MR analysis makes a number

of assumptions, which if incorrect can affect the results and
subsequent conclusions. There is an unlikely possibility for
confounding by population stratification. However, the sample
used for this study is mostly homogeneous, made up
overwhelmingly of people of European descent. Pleiotropic
effects, or violation of the exclusion-restriction assumption,
occur when the chosen genetic variant has a direct effect on the
outcome of interest via a pathway other than the exposure of
interest.

The two-sample analytic approach means I used summary

data about the relationship of the genetic variant to the
exposure of interest from one sample and summary data about the
relationship between the genetic variant and the outcome of
interest to determine the relationship between the exposure and
outcome. By design, the exposure of interest and the outcome are

5

not measured in the same sample. This limits my ability to
perform a rigorous subgroup analysis. However, the two-sample
method is more robust to chance associations than one sample
analyses.

Additionally, use of summary data from two samples

may result in sample overlap, which could bias the findings. The
sample size of both data sources is very large, and bias due to
sample overlap is not of major concern. The use of summary data
also makes it difficult to test whether associations vary by
sub-group. Although causal effects should be consistent they may
not be relevant in all populations.[136] Similarly, Mendelian
randomizations estimates for the effects of these amino acids
may vary according to their levels in different populations.
Finally, the NO Measurement Error (NOME) assumption,
specifically that there is no measurement error in the genetic
variant and exposure association, cannot be tested directly. An
adaptation of the I2 statistic from the field of meta-analysis
is proposed to quantify the strength of NOME violation for MREgger.[127]
One additional limitation of this study, and MR in general, is
that in most instances it specifies the endogenous effect on the
outcome when most times we are interested in the exogenous
effect.

6

Contributions
The dissertation contributes to knowledge of CAD and MI by using
a novel analytic method to obtain unconfounded estimates for
three amino acids where the epidemiological, clinical, and in
vitro studies have been inconclusive.

It has the advantage of

using a novel technique which enables estimates to be made costeffectively even when no study including both the exposure and
outcome is available. MR is not well suited for assessing the
magnitude of the effect, but rather the direction of the effect.
The statistically significant lower risk of CAD with higher
alanine requires replication to more clearly understand the
magnitude and pathway by which alanine affects CAD in order to
develop targeted treatments and pharmacotherapies.[76]

The

analyses for glutamine and glycine did not have statistically
significant findings, and is a call for additional studies,
possibly with larger samples, or stronger genetic instruments.
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